Evidence map›Paper›PMID 33369690›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

[

Laura Kuebler, Sabrina Buss, Andrei Leonov, Sergey Ryazanov, Felix Schmidt, Andreas Maurer, Daniel Weckbecker, Anne M Landau, Thea P Lillethorup, Daniel Bleher and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 1 synthesis or guideline pooled it, 90 citations in OpenAlex.

  1. Pooled it
  2. Preclinical evaluation of [EJNMMI research · 2026
    Article
  3. PET imaging of alpha-synuclein: from radiotracer design through in vitro and in vivo translation.European journal of nuclear medicine and molecular imaging · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Design, Synthesis and Evaluation of the First 2-Alkynyl(aza)indolePharmaceuticals (Basel, Switzerland) · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. PET tracer development for imaging α-synucleinopathies.Archives of pharmacal research · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 2 countries.

Laura Kuebler *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Sabrina Buss *Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Andrei Leonov *MODAG GmbH, Mikroforum Ring 3, 55234, Wendelsheim, Germany.
Sergey Ryazanov *MODAG GmbH, Mikroforum Ring 3, 55234, Wendelsheim, Germany.
Felix Schmidt *MODAG GmbH, Mikroforum Ring 3, 55234, Wendelsheim, Germany.
Andreas MaurerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Daniel WeckbeckerMODAG GmbH, Mikroforum Ring 3, 55234, Wendelsheim, Germany.
Anne M LandauTranslational Neuropsychiatry Unit, Aarhus University, Norrebrogade 44, 8000, Aarhus, Denmark.
Thea P LillethorupDepartment of Nuclear Medicine and PET-Centre, Aarhus University, Palle Juul-Jensens 165, J109, 8200, Aarhus, Denmark.
Daniel BleherWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Ran Sing SawWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Bernd J PichlerWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany.
Christian GriesingerDepartment of NMR-based Structural Biology, Max Planck Institute for Biophysical Chemistry, Am Faßberg 11, 37077, Göttingen, Germany. cigr@nmr.mpibpc.mpg.de.
Armin GieseMODAG GmbH, Mikroforum Ring 3, 55234, Wendelsheim, Germany. giese@modag.net.
Kristina HerfertWerner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University of Tübingen, Röntgenweg 13, 72076, Tübingen, Germany. kristina.herfert@med.uni-tuebingen.de.
University of Tübingen · DEMax Planck Institute for Biophysical Chemistry · DESiemens (Germany) · DEAarhus University · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDeposition of misfolded alpha-synuclein (αSYN) aggregates in the human brain is one of the major hallmarks of synucleinopathies. However, a target-specific tracer to detect pathological aggregates of αSYN remains lacking. Here, we report the development of a positron emission tomography (PET) tracer based on anle138b, a compound shown to have therapeutic activity in animal models of neurodegenerative diseases.

methodsSpecificity and selectivity of [

results[

conclusionMODAG-001 provides a promising lead structure for future compound development as it combines a high affinity and good selectivity in fibril-binding assays with suitable pharmacokinetics and biodistribution properties.

Indexed as

Lewy Body DiseaseNeurodegenerative Diseasesalpha-SynucleinAnimalsCarbon RadioisotopesMicePositron-Emission TomographyRadiopharmaceuticalsRatsTissue Distributionalpha-SynucleinCarbon RadioisotopesRadiopharmaceuticalsAlpha-synucleinParkinson’s diseasePET imagingTracer development

Identifiers

PMID33369690
PMCPMC8113290
OpenAlexW3114479339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.